Rachna T. Shroff: SWOG S1815 shows no OS benefit for nab-paclitaxel in BTCs
Ben Westphalen, Chair of Translational Research and Precision Medicine Working Group at ESMO, shared an article by Rachna T. Shroff et al. on X, adding the following:
“Open Access in JCO ASCO
SWOG S1815 found no OS or PFS benefit for adding nab-paclitaxel to gemcitabine-cisplatin (GAP vs GC) in advanced biliary tract cancers (BTCs). Median OS: 14.0 vs 13.6 months (P=0.41). GAP showed more toxicity.”
Authors: Rachna T. Shroff, Gentry King, Sarah Colby, Aaron J. Scott, Mitesh J. Borad, Laura Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Imane El Dika, Benjamin Tan, Puneet Cheema, Anuj Patel, Renuka Iyer, R. Katie Kelley, Jaykumar Thumar, Anthony El-Khoueiry, Katherine A. Guthrie, E. Gabriela Chiorean, Howard Hochster, Philip A. Philip
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023